Eli Lilly Shares Surge on Raised Sales Forecast

Eli Lilly & Co. raised its full-year sales forecast as demand for its blockbuster obesity and diabetes drugs continues to surge. Speaking on "Bloomberg Open Interest," Bloomberg's Madison Muller also discusses the implications for Novo Nordisk. (Source: Bloomberg)

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.